['type 2 diabetes mellitus']
['biochaperone insulin lispro', 'humalog®']

        Inclusion Criteria:

          -  Type 2 diabetes mellitus ≥ 12 months

          -  Treated with stable multiple daily insulin ≥ 3 months (basal-bolus therapy or only
             bolus insulin therapy)

          -  Current total daily insulin treatment <1.2 (I)U/kg/day

          -  Body Mass Index below or equal to 40.0 kg/m²

          -  HbA1c ≤ 9.0% by local laboratory analysis

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to trial products or related products

          -  Type 1 diabetes mellitus

          -  Previous participation in this trial

          -  The receipt of any investigational product within 60 days prior to this trial

          -  Clinically significant abnormal haematology, biochemistry, lipids, or urinalysis
             screening tests, as judged by the Investigator considering the underlying disease

          -  Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea,
             vomiting, heartburn or diarrhoea), as judged by the Investigator

          -  Presence of renal impairment (Estimated Glomerular filtration Rate (eGFR)<60
             milliliters/minute/1.73m²)

          -  Presence of late diabetic complications and/or acute coronary heart disease.

          -  Known slowing of gastric emptying and or gastrointestinal surgery that in the opinion
             of the investigator might change gastrointestinal motility and food absorption

          -  Unusual meal habits and special diet requirements or unwillingness to eat the food
             provided in the trial

          -  Current treatment with corticosteroids
      